NIM Norwood Imm.

RNS Number:5201F
Norwood Immunology Ld
03 July 2006


For immediate release                                               3 July 2006


                           NORWOOD IMMUNOLOGY LIMITED
                    ('Norwood Immunology' or 'the Company')

           CLINICAL STUDY RESULTS - BONE MARROW TRANSPLANT TREATMENT

                STUDY COMPLETE, CONFIRMS PREVIOUS POSITIVE DATA

Norwood Immunology Limited (AIM: NIM), the company focussed on the rejuvenation
of the immune system, today announces the completion of the pilot clinical study
in cancer patients undergoing chemotherapy and bone marrow transplantation
(BMT).  The study was used to determine whether a luteinising hormone releasing
hormone (LHRH) agonist can enhance the renewal of T cells, which are essential
for immune defence mechanisms. Analysis of the additional data shows positive
results and a significant increase in naive CD4+ T cells and further supports
the interim results as previously announced at the American Haematology Society
conference in December 2003.

This non-randomized, open labelled study was initiated to explore whether the
Company's technology was safe to use and could enhance immune recovery in
immunosuppressed patients, and so confirm the effects previously demonstrated
pre-clinically and in prostate patients, by the Company.  A major problem for
BMT patients is that the standard of care chemotherapy also causes permanent
damage to the immune system. While children recover adequate immunity from
approximately 6 months post BMT, adults rarely regain specific immune defence
mechanisms. This immune suppression of BMT leads to high incidence of
infections, and may underlie cancer relapse and poor responses to vaccines
including those to cancer.

The study, which was conducted at in 83 patients, aged 18 years or older, with
either leukaemia, lymphoma or multiple myeloma (40 treated; 43 control) was
carried out for approximately 13 months in male or female patients at the Alfred
Hospital and Peter MacCallum Cancer Institute in Melbourne.  Patients received
standard of care cancer high-dose myeloablative chemotherapy, with or without a
course of an LHRH agonist and either autologous (self-derived) or allogeneic
(from a donor) BMT, The primary endpoint was to determine whether the LHRH
agonist could induce renewed thymic function and output of new naive CD4+ T
cells (which are required for all immune responses), compared to similar
patients not receiving the LHRH.  Secondary endpoints included extensive
analysis of other immune cells in the blood.

The results of the study are currently being fully analyzed and a manuscript
prepared for submission to a peer reviewed journal.  Analysis of the key data
however, demonstrated a significant increase in naive CD4+ T cells and CD4+
TRECs, confirming the interim results reported previously.

Principal Investigator, Associate Professor Anthony Schwarer, Head, Bone Marrow
Transplant Programme, Alfred Hospital commented:  "Many patients become
seriously immune compromised as a result of the transplant regime, and a
treatment that will improve recovery and reduce post-transplant infections would
be important.  The results of this exploratory study are encouraging.  Even
though we had a mixed patient group with different prognostic outcomes and the
patients were not randomized, the effect we saw on the increase of CD4+ T cells
numbers and TRECS is a world first.  It will be important to now confirm and
even quantitate, if possible, this rate of immune recovery and its clinical
benefits in an adequately powered double blind, placebo controlled study in a
more homogeneous patient population /group."

Richard Williams, CEO of Norwood Immunology, commented: "Completing this study
is an important milestone for the Company. The early results and the foundation
work established by this exploratory study has also enabled Norwood Immunology
to develop a fully randomised, placebo controlled, high quality multi-centre
study which opened at the MD Anderson and Dana-Farber Cancer Institute in the
USA earlier this year.  We are pleased that our Australian study, championed by
Associate Professor Tony Schwarer has lead the way to this FDA accepted study,
which is being conducted in conjunction with our US licence partner, TAP
Pharmaceutical Products Inc, our Principal Investigator and other leading
clinicians."

For further information please contact:

Richard Williams, Chief Executive Officer, Norwood Immunology Limited
+44 (0) 7860 295153

Lisa Baderoon, Mark Court, Mary-Jane Johnson, Buchanan Communications
+44 (0) 207 466 5000

Notes for editors:

Norwood Immunology has licensed its immunology intellectual property to TAP
Pharmaceutical Products Inc. for commercialization in the United States,
utilizing TAP's GnRH analogue, Lupron Depot(R) (leuprolide acetate for depot
suspension).  This combined initiative is exploring the use of Lupron Depot in
regenerating the thymus gland and in turn "re-booting" the body's immune system,
enabling patients to better recover from life-threatening diseases.

TAP Pharmaceutical Products Inc., located in Lake Forest, IL., U.S.A., is a
joint venture between Abbott, headquartered in Abbott Park, IL., U.S.A ., and
Takeda Pharmaceutical Company Limited of Osaka, Japan.  TAP currently markets
Lupron Depot and Prevacid(R) (lansoprazole).  For more information about TAP and
its products, please visit the company's web site at www.tap.com.






                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

MSCFMMRTMMJJBBF

Grafico Azioni Norwood Immunology (LSE:NIM)
Storico
Da Mag 2024 a Giu 2024

Grafico Azioni Norwood Immunology (LSE:NIM)
Storico
Da Giu 2023 a Giu 2024